Cannabis-based medicine will soon be available in France, as the country’s health officials recently approved commercial sales of the drug for the first time in history.

A report from the Associated Press indicates that Britain’s GW Pharmaceuticals has been granted permission from the Health Ministry to begin marketing its latest drug, Sativex, a cannabinoid medicine used to treat specific symptoms of multiple sclerosis.

Approval of the drug has already been granted in 23 other countries, including Spain, Germany, Canada, Switzerland and the UK. In the United States, Sativex is expected to receive approval from the FDA for the treatment of cancer pain once the final stages of its clinical trials are complete.

Sativex is comprised of an equal 1:1 ratio of the two most common cannabinoids found in marijuana -- THC and cannabidiol. In addition to the treatment of multiple sclerosis and cancer pain, the drug is also being tested as a treatment option for patients suffering from brain cancer.

GW Pharmaceuticals has certainly established itself as a worldwide leader in the development of cannabis-based medicine, and it is showing no signs of slowing down anytime in the near future. This week, the company announced a follow-on offering of 2,441,110 shares on the NASDAQ Global Market, raising nearly $88 million. GW’s stock has increased 423% since the company was listed on the Nasdaq last summer.

Mike Adams writes for stoners and smut enthusiasts in High Times, Playboy’s The Smoking Jacket and Hustler Magazine. You can follow him on Twitter @adamssoup and on Facebook/mikeadams73.